Sensei Dr Michiya Expert Workshop: Mastering Complex CTO Techniques

omegakimia@yahoo.com
Posted in Workshop

Thank you Orbus Neich & Dato Sri Dr Azhari Rosman from IJN for organizing this CTO workshop with Sensei Dr Michiya Kageyama from Nasu Red Cross Hospital, Japan!

It was great learning from sensei regarding CTO techniques, with tips & tricks! Our in-house CTO enthusiast Dr Mugilan Sundarajoo also came to join us!

Did a CTO case via retrograde approach using Reverse CART technique

CTO stands for chronic total occlusion, which is a complete or near-complete blockage in a coronary artery that lasts three months or longer. Coronary arteries are the blood vessels that supply blood to the heart.

Reverse controlled antegrade and retrograde tracking (CART) is a technique used to treat chronic total occlusions (CTOs) in the coronary arteries:

How it works
This technique involves retrograde dissection to create a subintimal space, then navigating a retrograde microcatheter over the dissection. Next, an antegrade dissection is performed, and an antegrade balloon is inflated in the subintimal space. Finally, the subintimal space is connected, and a retrograde wire is used to navigate into the proximal true lumen.

Dr Michiya

Hope to learn more from all the sensei!!

Comprehensive Demo on Bifurcation Stenting: Advanced Techniques

omegakimia@yahoo.com
Posted in Workshop

Glad to be given the opportunity to share on types of bifurcation stenting, mainly focusing on provisional stenting, DK crush & Culotte stenting today at IJN, organized by Medtronic.

Thanks to Datuk Dr Shaiful, Datuk Dr Kumara, Dato Sri Dr Azhari Rosman & Dato Dr Amin!

Good to play on the model and test out some issues/rewiring issues as well. I still remember my 1st DK Crush was done with Dr Lee Tjen Jhung!

Managed to let the fellows to do a few techniques with the models

Bifurcation Stenting

Overall it was a great experience!

Hope to join more in future!

Forxiga for Chronic Kidney Disease (CKD): A Breakthrough in Kidney Health Management

omegakimia@yahoo.com
Posted in Drug Talk

Forxiga (dapagliflozin) has emerged as a game-changer in managing chronic kidney disease (CKD). Traditionally used as a treatment for Type 2 diabetes, Forxiga is now recognized for its kidney-protective benefits, offering hope to millions of CKD patients worldwide. Glad to be able to share with group of doctors from LifeCare Diagnostic, led by Dr Ong!

How Forxiga Works in CKD
Forxiga belongs to a class of medications known as SGLT2 inhibitors, which work by helping the kidneys remove excess glucose through urine. Beyond its glucose-lowering effects, Forxiga has been shown to reduce the progression of kidney disease by improving kidney function, lowering protein in the urine, and reducing the risk of kidney failure.

Forxiga’s Clinical Benefits in CKD
Recent studies have demonstrated Forxiga’s ability to significantly delay CKD progression. This means fewer patients advancing to end-stage renal disease (ESRD) and reduced dependence on dialysis or kidney transplants. It has also been shown to lower cardiovascular risks, which is a common complication for CKD patients.

Who Can Benefit from Forxiga?
Forxiga is not just for diabetic patients. Recent guidelines recommend its use in CKD patients with or without diabetes, making it an essential treatment option for a broader patient population.

forxiga

Conclusion
Forxiga offers a promising solution for those suffering from chronic kidney disease. With its ability to slow disease progression and improve overall kidney health, Forxiga is a vital part of modern CKD treatment strategies.

Great discussion, great sharing & great food!

Understanding Lipitor: Key Insights for Caring Pharmacists on Patient Care

omegakimia@yahoo.com
Posted in Drug Talk

Its my 1st time to visit Caring Pharmacy HQ at Petaling Jaya for a sharing session on lipitor for the pharmacist!

Thanks for the invitation from Viatris for me to share & discuss on this highly debatable topic among patients. haha

lim wei juan

It was attended both by physical & virtual for outstation pharmacists.

lipitor

Overall, it was a very engaging sessions with tons of questions from participants, hopefully get some messages across them!

Enhance Your Skills: The SEQuent Please NEO Workshop for Advanced DCB Techniques

omegakimia@yahoo.com
Posted in Workshop

The SEQuent Please NEO Drug-Coated Balloon (DCB) is revolutionizing vascular intervention, and I recently had the chance to dive deep into its potential at a dedicated workshop. Thanks to Dato Sri Dr Azhari Rosman, Dato Dr Amin, Datuk Dr Shaiful, Datuk Dr Kumara & BBraun team!

This cutting-edge device, designed for precise drug delivery without the need for a stent, offers a promising solution for treating coronary artery disease.

SEQuent Please NEO

The workshop covered the unique features of the SEQuent Please NEO DCB, including its ultra-thin balloon coating and innovative drug delivery system, which ensure optimal healing and minimal vessel damage. We also reviewed clinical cases, showing how the device effectively treats in-stent restenosis and other complex lesions.

What impressed me most was the emphasis on patient outcomes and the growing body of evidence supporting the SEQuent Please NEO’s efficacy and safety. It was a great opportunity to learn from industry experts and gain hands-on experience with this advanced technology.

Thanks once again to the organizer for the invitation, I have learnt alot as well from this workshop!

AGENT DCB: Advanced Technology for Superior Vascular Care

omegakimia@yahoo.com
Posted in Workshop

Recently I had the opportunity to attend the AGENT DCB Workshop, and it was an eye-opener. The session was packed with valuable insights on the latest advancements in drug-coated balloon technology, specifically the AGENT DCB, which is designed to optimize vascular intervention outcomes.

agent dcb

The workshop featured updates on clinical data, case studies and interactive discussions led by leading interventional cardiologists. It was fascinating to see how the AGENT DCB offers superior drug delivery and vessel healing, addressing the limitations of traditional balloon angioplasty. We explored its clinical applications, benefits, and recent trial data that highlight its effectiveness in treating complex lesions.

Overall, the workshop was an excellent opportunity to learn, network, and stay updated on cutting-edge innovations in vascular care. If you get the chance to attend a similar event, I highly recommend it!

Empagliflozin for CKD: Benefits, Research, and Patient Outcomes

omegakimia@yahoo.com
Posted in Drug Talk

Had a golden opportunity to share a case on how we manage patient with CKD from cardiologist point of view along with Dato Sri Dr Azhari Rosman!

It was a well organized talk attended by a group of 20 Gps!

Empagliflozin is an SGLT-2 inhibitor originally used for managing type 2 diabetes. Recent studies have shown its efficacy in treating chronic kidney disease (CKD), regardless of diabetic status. By reducing blood glucose levels, empagliflozin also helps to lower blood pressure, reduce proteinuria, and mitigate the progression of kidney damage.

ckd

Great Q&A sessions about SGLT2i and as well as general cardiology questions.

The EMPA-KIDNEY trial demonstrated significant benefits, showing that empagliflozin slows down CKD progression, reduces cardiovascular risk, and lowers the likelihood of hospitalization due to heart failure. Its kidney-protective effects are believed to stem from reducing intraglomerular pressure, improving metabolic parameters, and decreasing inflammation and fibrosis in the kidneys.

I have learnt alot from Dato Sri as well as the GPs!

Overall, empagliflozin represents a promising treatment option for CKD patients, with or without diabetes, offering improved renal and cardiovascular outcomes.

Grateful for the opportunity given and hope to have more in future!